Leads Biolabs Highlights R&D Momentum with Six Abstracts Accepted by 2026 ESMO, Including Two Top-Tier Oral Presentations

Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs”, HK: 09887) reported that six of its latest oncology studies have been selected for presentation at the 2026 annual meeting of the European Society for Medical Oncology (ESMO), scheduled for 23–27 October 2026 in Madrid.

Two of the studies secured Proffered Paper slots—the highest level of oral presentation—while the remaining four will be presented as posters. The research covers extrapulmonary neuroendocrine carcinoma (EP-NEC), biliary tract cancer (BTC) and relapsed/refractory multiple myeloma (RRMM). In addition, ESMO granted Late-Breaking Abstract eligibility for one investigation, with the full LBA to be submitted in September 2026.

The company emphasised that the selections underscore international recognition of its clinical data quality and its immuno-oncology pipeline. Detailed results will be released upon ESMO’s abstract publication and during the conference.

Leads Biolabs also reiterated that its bispecific antibody LBL-024 (Opamtistomig) has been chosen for an oral presentation at the World Conference on Lung Cancer in September 2026, focusing on a first-line non-small cell lung cancer (1L NSCLC) study. The corresponding abstract is slated for release on 19 August 2026.

Pipeline overview

1. LBL-024 (Opamtistomig) • Bispecific antibody targeting PD-L1 and 4-1BB, developed via the X-body™ platform. • First 4-1BB agonist globally to reach a pivotal single-arm registrational stage; potential first approval for EP-NEC. • Active clinical development across 13 solid-tumour indications in China, including one registrational and eight proof-of-concept trials. • Regulatory milestones: Breakthrough Therapy Designation from China’s CDE (Oct 2024), FDA Orphan Drug Designation for NEC (Nov 2024), FDA Fast Track Designation for EP-NEC (Jan 2026) and EU Orphan Drug Designation (Jan 2026).

2. LBL-034 • Bispecific T-cell engager targeting GPRC5D and CD3, designed with a 2:1 format on the LeadsBody® platform. • Under Phase I/II trials for RRMM after demonstrating encouraging activity in preclinical and early-stage clinical settings. • Received FDA Orphan Drug Designation (Oct 2024) and FDA Fast Track Designation (Jan 2026).

Leads Biolabs cautioned that successful development and commercialisation of LBL-024 and LBL-034 remain subject to regulatory review and clinical outcomes.